174732-96-8

Usage

Uses

Used in Pharmaceutical Industry:
N-Boc-3-hydroxy-DL-phenylalanine is used as a chiral building block for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapies. Its unique structure allows for controlled modification of phenylalanine, enabling the creation of innovative and effective medications.
Used in Peptide Synthesis:
In the field of peptide synthesis, N-Boc-3-hydroxy-DL-phenylalanine is utilized as a key intermediate. Its presence in peptide structures can influence the properties and functions of the resulting peptides, making it an essential component in the design and synthesis of bioactive peptides.
Used in Organic Synthesis:
N-Boc-3-hydroxy-DL-phenylalanine is also employed in organic synthesis, where it serves as a versatile intermediate for the preparation of various organic compounds. Its ability to be modified and incorporated into complex molecular structures makes it a valuable tool for chemists working on the development of new organic compounds with potential applications in various industries.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 775-06-4 D/L-3-hydroxy-phenylalanine 

Downstream Products

• 325464-47-9 N-Boc-D,L-m-Tyr(O-2-Pyrim)-OH 
• 141088-10-0 (4S,10S)-10-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-7-(3-hydroxy-benzyl)-3,3-dimethyl-6,9-dioxo-1,2-dithia-5,8-diaza-cycloundecane-4-carboxylic acid 
• 1571933-52-2 C₂₄H₄₀INO₅Si 
• 1571933-94-2 C₁₈H₂₀INO₆S 
• 1571933-89-5 C₂₇H₃₆BrNO₈S 
• 1571933-90-8 C₂₇H₃₆BrNO₈S 
• 1571933-87-3 tert-butyl 2-(tert-butoxycarbonylamino)-3-(2-bromo-5-(2-(4-methylphenylsulfonyloxy)ethoxy)phenyl)propanoate 
• 1571933-84-0 C₁₈H₂₆BrNO₅ 
• 1571933-82-8 C₂₄H₄₀BrNO₅Si 
• 1571933-96-4 C₂₇H₄₉NO₅SiSn 
• 1571933-71-5 C₂₄H₄₀INO₅Si 
• 1571933-73-7 C₂₄H₄₀INO₅Si 
• 1571933-62-4 C₂₀H₂₉BrINO₅ 
• 1571933-60-2 C₂₀H₂₉ClINO₅ 

Relevant academic research and scientific papers

AROMATIC AMINO ACID DERIVATIVE AND POSITRON EMISSION TOPOGRAPHY (PET) PROBE UTILIZING SAME

A compound having a structure represented by the general formula (I): (wherein n is 0 or 1; R1 represents a hydrogen atom (only if n = 0), a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, an optionally substituted amino group, an o

TYROSINE DERIVATIVE AND METHOD FOR PRODUCING TYROSINE DERIVATIVE

The objective of the present invention is to provide a tyrosine derivative which is useful as a melatonin MT1 receptor antagonist, and a method for producing a specific tyrosine derivative with high yield by efficiently introducing an iodine atom at the para position of the phenolic hydroxy group in the benzene ring of tyrosine with good regioselectivity. The tyrosine derivative of the present invention is characterized in being represented by the following formula (I): wherein R1 is a protective group of the amino group and the like; R2 is a protective group of the carboxy group and the like; R3 is a hydrogen atom and the like; R4 is a halogen atom and the like; A is —(CH2)l—[Z(CH2)m]n—; X is a leaving group.

SUBSTITUTED HETEROCYCLIC COMPOUNDS

The present invention relates to substituted heterocyclic compounds of Formula I or XI: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine II4 receptor inhibitors useful in the treatment of histamine II4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

Synthesis of tyrosine-derived tetrahydroisoquinolines by Lewis acid catalyzed cyclization of N-(phenylsulfonyl)alkyloxazolidinones

N-Boc-protected tyrosine esters 5a,b were converted into tetrahydroisoquinolines 13 and 14 in four steps by reduction and ring closure to oxazolidinones 9 and 10, addition of benzenesulfinic acid and aldehydes to sulfones 11 and 12 and subsequent Lewis ac

Hydroxyphenyl derivatives with HIV integrase inhibitory properties

An hydroxyphenyl derivative selected from the group consisting of a compound of formula and when a compound of formula I comprises a carboxylic acid group pharmaceutically acceptable salts thereof and when a compound of formula I comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein n is 1, 2 or 3, e is 1, 2 or 3, Hal represents a halogen atom (e.g. Cl, Br, F or I), p is 0, 1 or 2, r is 0, 1 or 2, X and X′ each independently represents a single bond, a saturated straight or branched hydrocarbon group of 1 to 4 carbon atoms or a straight or branched hydrocarbon group of 2 to 4 carbon atoms comprising a carbon to carbon double bond, Rarepresents H or —CH3, and Raarepresents H or —CH3; W may represent an amino acid residue or fragment. These compounds may be used to inhibit the activity of HIV integrase.

Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship

Based on structure-activity relationship studies, we designed and synthesized plasmin (PL) and plasma kallikrein (PK) inhibitors. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-PIC)-octylamide inhibited PL, PK, urokinase (UK) and thrombin (TH) with IC50 values of 0.53, 30, 5.3 and >400 μM, respectively. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-2-Pyrim)-4-carboxyanilide inhibited PL, PK, UK and TH with IC50 values of 36, 0.56, 440 and >1000 μM, respectively.